arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Enovis CORP

ENOV
$26.62 ▲ +0.29 (+1.08%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
17 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enovis CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 6.7%
Op. Margin -50.0%
ROIC -41.1%
FCF / Share $0.35
Trailing P/E
Price / Book 1.0x
FCF Yield 1.3%
Debt / Equity 0.87
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.25B
↑ +6.7%
Net Income Profit after all expenses
$-1.18B
↓ -43.5%
Operating Margin Operating profit as % of sales
-50.0%
↓ -35.9% 5th
FCF / Share Free cash flow per share
$0.35
↑ +128.7%
Long-Term Debt Long-term obligations
$1.30B
↓ -2.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
11
Financial Health
27
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 63 quarters